STOCK TITAN

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) to present company overview at Jefferies London Healthcare Conference. CEO David-Alexandre C. Gros, M.D. to speak on November 16, 2023, at 8:00 a.m. GMT. Webcast registration available. Webcast replay accessible on the Company's website.
Positive
  • None.
Negative
  • None.

IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming Jefferies London Healthcare Conference on Thursday, November 16, 2023, at 8:00 a.m. GMT (3:00 a.m. EST).

To register in advance for the presentation webcast, sign up here.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/news-and-events/events.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology, to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedInTwitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253 8881
jurban@berrypr.com

Source: Eledon Pharmaceuticals


FAQ

What is the event Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) will be presenting at?

Eledon Pharmaceuticals, Inc. will be presenting a company overview at the Jefferies London Healthcare Conference.

Who will be speaking at the event?

Dr. David-Alexandre C. Gros, the Chief Executive Officer, will be presenting the company overview.

When will the presentation take place?

The presentation will take place on November 16, 2023, at 8:00 a.m. GMT.

Where can I register for the webcast?

You can register for the webcast in advance at the provided link.

Where can I access the webcast replay?

The webcast replay will be accessible on the Events page of the Investors section on the Company's website.

Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

ELDN Rankings

ELDN Latest News

ELDN Stock Data

57.32M
18.02M
5.43%
38.76%
0.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
IRVINE

About ELDN

eledon pharmaceuticals, inc. is a clinical stage biotechnology company using its expertise in targeting the cd40l pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. our lead program, at-1501, is a potential best-in-class humanized igg1 anti-cd40l antibody with high affinity for cd40l, a well-validated biological target with broad therapeutic potential. the cd40/cd40l pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.